WAYNE, Pa. (AP) — WAYNE, Pa. (AP) — Aclaris Therapeutics Inc. (ACRS) on Thursday reported a loss of $14.6 million in its third quarter.
On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 12 cents.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share.
The specialty pharmaceutical company posted revenue of $3.3 million in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $1.6 million.
The company's shares closed at $2.26. A year ago, they were trading at $2.22.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ACRS at https://www.zacks.com/ap/ACRS
/AI%20(artificial%20intelligence)/Artificial%20intelligence%20and%20machine%20learning%20concept%20-%20by%20amgun%20via%20iStock.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/Oracle%20Corp_%20logo%20on%20phone-by%20WonderPix%20via%20Shutterstock.jpg)
